Nova Eye Medical (ASX:EYE) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EYE Nova Eye Medical Ltd ASX:EYE
51 GF Score
Price A$0.12
GF Value A$0.19
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical FFO per Share?

FFO per Share only applies to REITs.

ASX:EYE
51GF Score
Nova Eye Medical Ltd ASX:EYE
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.12 is trading 39.5% below its estimated GF Value™ of A$0.19. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

  • FFO per Share:
  • GF Value™: A$0.19 vs. price of A$0.12 (39.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
51GF Score

Get the complete analysis for ASX:EYE

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.19
GF Value